Approval of Tumor Dissolving Virus｜June 8, 2026

Performance Overview

Oncolys BioPharma announced that it has obtained approval for the manufacturing and sale of the tumor dissolving virus 'Telomerasin Injection' targeting esophageal cancer on June 8, 2026. This is the world's first tumor dissolving adenovirus product for esophageal cancer, developed based on clinical trial results from 17 domestic facilities, and received standard approval upon application. Sales are scheduled to start from the December 2026 fiscal year after drug pricing is listed, with expectations to contribute to future revenue. Following the approval, the company will receive milestone income from Fujifilm Toyama Chemical, and pre-receipt of funds is anticipated within this fiscal year. The specific impact on performance for this fiscal year remains undecided.

Future Outlook and Investor Impact

The company aims to contribute to the expansion of the esophageal cancer treatment market by providing a new treatment option through this approval. Preparations for sales are underway, with revenue recognition expected from the December 2026 fiscal year. Future revenue realization and clinical data progress are critical factors that could enhance corporate value. For investors, this milestone marks significant progress from clinical development to commercialization, and attention will be focused on the start of sales and revenue generation.